Skip to NavigationSkip to content

German biotech Apceth appoints Prof. Ralf Huss

Published on: 19/10/11

Munich-based biotech Apceth has appointed Prof Ralf Huss to its management board.

Prof Huss moves to the company from Roche, where he served as global head of the pharma firm’s therapeutic cell initiative.

He already has a long-standing relationship with Apceth, which specialises in the translational development and manufacturing of innovative cell therapy products, and in his new role will focus on the pre-clinical and early development of cell-based therapeutics and external innovation.

Apceth majority shareholder Dr Thomas Strüngmann explained: “Ralf Huss has been a founding member of Apceth. We are delighted that he has now decided to join the operational team in Apceth.”

 Prof Huss worked at Roche Diagnostics GmbH in Pharmaceutical Research & Early Development (pRED) in Penzberg, Germany from 2005.

In addition to his other positions, he remains adjunct professor for regenerative medicine at Wake Forest Institute for Regenerative Medicine in Winston-Salem in the US.

Apceth was set up in 2007 as a start-up company with funding from  the founders and former owners of pharmaceutical manufacturer Hexal, including Dr Strüngmann, which Novartis acquired in 2005.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches